Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Monotherapy in HCC with Child-Pugh B and ALBI Grade 1/2
NCT05622071Phase 2Completed
- Sponsor
- Unicancer
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Unicancer. Started Oct 2023; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05622071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622071.